

Dagoberto Callegaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7217808/publications.pdf>

Version: 2024-02-01

29
papers

714
citations

759055

12
h-index

552653

26
g-index

29
all docs

29
docs citations

29
times ranked

1222
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 229-232.	0.3	5
2	Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 598-606.	0.3	1
3	Prevalence of multiple sclerosis in key cities of Brazil: a study in Passo Fundo, Southern Brazil. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 692-696.	0.3	1
4	Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	23
5	Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103252.	0.9	3
6	Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103146.	0.9	10
7	Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 1040-1061.	0.3	5
8	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	0.9	110
9	Characterization of pain syndromes in patients with neuromyelitis optica. <i>European Journal of Pain</i> , 2020, 24, 1548-1568.	1.4	16
10	Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach. <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 430-439.	0.3	7
11	Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1907-1914.	1.4	45
12	The protective effects of high-education levels on cognition in different stages of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 41-48.	0.9	29
13	A severe phenotype of Kennedy disease associated with a very large CAG repeat expansion. <i>Muscle and Nerve</i> , 2018, 57, E95-E97.	1.0	11
14	Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 539-554.	0.3	22
15	Longitudinal analysis of verbal episodic memory in patients with relapsing-remitting multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 302-309.	0.3	2
16	MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2018, 9, 217.	1.1	156
17	A disturbed processing of graviceptive pathways may be involved in the pathophysiology of balance disorders in patients with multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 106-111.	0.3	5
18	Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study. <i>BMC Health Services Research</i> , 2016, 16, 102.	0.9	19

#	ARTICLE	IF	CITATIONS
19	Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1257-1259.	0.9	89
20	Hypovitaminosis D association with disease activity in relapsing remitting multiple sclerosis in Brazil. Journal of the Neurological Sciences, 2016, 363, 236-239.	0.3	8
21	Leukoencephalopathy resolution after atypical mycobacterial treatment: a case report. BMC Neurology, 2015, 15, 159.	0.8	1
22	Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration. Frontiers in Cellular Neuroscience, 2015, 9, 289.	1.8	51
23	Tongue forces and handgrip strength in normal individuals: association with swallowing. Clinics, 2015, 70, 41-45.	0.6	15
24	Oligoclonal Bands in Cerebrospinal Fluid of Black Patients with Multiple Sclerosis. BioMed Research International, 2015, 2015, 1-5.	0.9	8
25	Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger Than Age 18 Years. Pediatric Neurology, 2015, 53, 166-168.	1.0	39
26	Anti-MOG (Myelin Oligodendrocyte Glycoprotein) Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star. Neuro-Ophthalmology, 2015, 39, 285-288.	0.4	12
27	Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients. Arquivos De Neuro-Psiquiatria, 2014, 72, 960-965.	0.3	10
28	Pathologic yawning in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2014, 3, 527-532.	0.9	9
29	Oral fingolimod to treat multiple sclerosis: see your cardiologist first. Arquivos De Neuro-Psiquiatria, 2014, 72, 651-652.	0.3	2